TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9739972

Group type: EXPERIMENTAL
Intervention: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 7979521

Group type: EXPERIMENTAL
Intervention: Height for age z score < -2
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Weight for age z scores
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Age above 8 years
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: High peripheral white cell count
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 128
Study: 2522371

Group type: EXPERIMENTAL
Intervention: 5% glucose containing 10 U l‐1 insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: 10% glucose with 40 U l‐1 insulin
Number of subjects: 17
Study: 5792911

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (0.9% solution, 10 ml)
Number of subjects: 15
Study: 30045107

Group type: EXPERIMENTAL
Intervention: Injectable leukocyte platelet-rich fibrin (iL-PRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 26693643

Group type: EXPERIMENTAL
Intervention: Milk-based liquid meal supplement (Sustagen Sport)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte sports drink (Powerade)
Number of subjects: 7
Study: 25547902

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally, intermittent administration on days 2 to 16 every 21 days, combined with docetaxel 75 mg/m² every 21 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Erlotinib 150 mg/d orally, administered continuously
Number of subjects: 68
Study: 22757691

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion on CV4 and CV8 3 times per week for 4 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion on CV4 and CV8
Number of subjects: 44
Study: 20083678

Group type: EXPERIMENTAL
Intervention: Simultaneous atrioventricular antitachycardia pacing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Convergent atrioventricular antitachycardia pacing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: New pacing algorithm
Number of subjects: 63
Study: 18477409

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA-enriched foods
Number of subjects: 44

Group type: COMPARATOR
Intervention: standard foods (control)
Number of subjects: 44
Study: 15727975

Group type: EXPERIMENTAL
Intervention: Persuasive newsletters and a parent-teenager driving agreement
Number of subjects: 469

Group type: COMPARATOR
Intervention: Standard information on driver safety
Number of subjects: 469
Study: 12580986

Group type: EXPERIMENTAL
Intervention: Gliclazide MR (30 mg initial dose)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Gliclazide MR
Number of subjects: 634
Study: 10534989

Group type: EXPERIMENTAL
Intervention: Bracketed enamel sample with pre-formed caries-like lesions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-bracketed enamel sample with pre-formed caries-like lesions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control sample (not placed in the mouth)
Number of subjects: 15
Study: 8600874

Group type: EXPERIMENTAL
Intervention: Knee brace applied to the tracking limb
Number of subjects: 20

Group type: COMPARATOR
Intervention: No knee brace
Number of subjects: 20
Study: 1914837

Group type: EXPERIMENTAL
Intervention: Galactosaminoglycuronoglycan sulfate (Matrix)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7159686

Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine tablet (300 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral quinidine sulfate solution (300 mg)
Number of subjects: 18
Study: 31130274

Group type: EXPERIMENTAL
Intervention: Coordinated care
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 283
Study: 29726951

Group type: EXPERIMENTAL
Intervention: Walnut consumption (42 g walnuts/d)
Number of subjects: 18
Study: 25536669

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 3 mg daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: rosiglitazone (Rosi) 4 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of rhGH and Rosi
Number of subjects: 31

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 31
Study: 23582949

Group type: EXPERIMENTAL
Intervention: Intermittent Hormonal Therapy (IHT) with cyproterone acetate (CPA) 200 mg/d for 2 weeks, then monthly LHRH analogue plus CPA 200 mg/d.
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Continuous Maximal Androgen Blockade (MAB) with CPA 200 mg/d plus monthly LHRH analogue.
Number of subjects: 1045
Study: 24009704

Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy (MBCT)
Number of subjects: 130
Study: 20204959

Group type: EXPERIMENTAL
Intervention: Long HPV pamphlet
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Short HPV pamphlet
Number of subjects: 499

Group type: COMPARATOR
Intervention: Long control pamphlet
Number of subjects: 499

Group type: COMPARATOR
Intervention: Short control pamphlet
Number of subjects: 499
Study: 18698881

Group type: EXPERIMENTAL
Intervention: Slow-escalation treprostinil dosing regimen
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rapid-escalation treprostinil dosing regimen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 23
Study: 16538016

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 2% mepivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia maintained with 2 L of oxygen, 4 L of nitrous oxide, and 1% to 3% isoflurane
Number of subjects: 20
Study: 12824786

Group type: EXPERIMENTAL
Intervention: GM‐CSF (300 microg by subcutaneous injection three times weekly for 4 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: STI-only group
Number of subjects: 33
Study: 10632688

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ELA-Max cream (lidocaine 4%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (EMLA and ELA-Max combined)
Number of subjects: 10
Study: 9121848

Group type: EXPERIMENTAL
Intervention: Electronic Recording Meter (ERM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Simple Mini-Wright (SM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both ERM and SM
Number of subjects: 65
Study: 8389667

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.5 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1 to 3
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.5 g/m2 days 1 to 3
Number of subjects: 25
Study: 3555033

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous tobramycin plus azlocillin
Number of subjects: 20
Study: 30473366

Group type: EXPERIMENTAL
Intervention: Learning Together intervention
Number of subjects: 6667

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 6667
Study: 26754643

Group type: EXPERIMENTAL
Intervention: Living kidney donors
Number of subjects: 124
Study: 23643477

Group type: EXPERIMENTAL
Intervention: Paid advertising (newspaper, radio, television)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Unpaid advertising (staff visits, flyers, brochures, free media coverage, presentations)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Overall screening and enrollment
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Retention strategies
Number of subjects: 145
Study: 25048382

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 130-139 mmHg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) >140 mmHg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) <40 mmHg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) >60 mmHg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) >140 mmHg with A1C increase
Number of subjects: 1791
Study: 22172244

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) using alteplase
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 209
Study: 20796106

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) covering the Ti-mesh
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 30
Study: 17561002

Group type: EXPERIMENTAL
Intervention: IUI with COH
Number of subjects: 265

Group type: COMPARATOR
Intervention: IUI without COH
Number of subjects: 265
Study: 15723891

Group type: EXPERIMENTAL
Intervention: Expressive writing focused on traumatic life events
Number of subjects: 47

Group type: COMPARATOR
Intervention: Writing about a neutral topic
Number of subjects: 47
Study: 12081192

Group type: EXPERIMENTAL
Intervention: Specialist nurses
Number of subjects: 880

Group type: COMPARATOR
Intervention: Senior house officers (SHOs)
Number of subjects: 880
Study: 11783144

Group type: EXPERIMENTAL
Intervention: Yinhua mixture aerosol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gentamycin aerosol
Number of subjects: 102
Study: 8874109

Group type: EXPERIMENTAL
Intervention: Maternal diet with complete avoidance of milk and eggs during the last trimester of pregnancy and exclusive breast feeding.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal diet with complete avoidance of milk and eggs starting after delivery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dietary restrictions for mothers.
Number of subjects: 0
Study: 20054944

Group type: EXPERIMENTAL
Intervention: 3 days bed rest
Number of subjects: 51

Group type: COMPARATOR
Intervention: 7 days bed rest
Number of subjects: 51
Study: 6151842

Group type: EXPERIMENTAL
Intervention: 40 mg of temazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31658024

Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 15 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 30 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride plus 2-W laser for 60 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 15 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 30 seconds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride plus 5-W laser for 60 seconds
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoride only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5-W laser groups
Number of subjects: 120
Study: 28929925

Group type: EXPERIMENTAL
Intervention: Participant-directed occupational therapy intervention
Number of subjects: 0
Study: 26861417

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) bathing
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no CHG bathing)
Number of subjects: 33
Study: 24479576

Group type: EXPERIMENTAL
Intervention: Narrative Therapy (NT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63
Study: 22526883

Group type: EXPERIMENTAL
Intervention: Bright light pulse (∼10,000 lux) for 0.2 h
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bright light pulse (∼10,000 lux) for 4.0 h
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bright light exposure (varying durations)
Number of subjects: 39
Study: 19770162

Group type: EXPERIMENTAL
Intervention: Ashworth Scale (AS) for elbow flexors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ashworth Scale (AS) for knee extensors
Number of subjects: 30
Study: 17599423

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control targeting HbA1c <6%
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glycemic control targeting HbA1c 7.0%-7.9%
Number of subjects: 10251
Study: 15961761

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) plus ifosfamide 5 g/m(2) during 24 hours and cisplatin 75 mg/m(2) every 3 weeks for three courses (TIP)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Ifosfamide 5 g/m(2) during 24 hours plus cisplatin 75 mg/m(2) (IP)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Paclitaxel, ifosfamide, and cisplatin (TIP)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Ifosfamide and cisplatin (IP)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Patients assessable for response (n = 189)
Number of subjects: 219
Study: 11992097

Group type: EXPERIMENTAL
Intervention: PNU-83757 (10 mcg, 60-140 mcg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PNU-83757
Number of subjects: 66
Study: 9789364

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 84

Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 84
Study: 11995905

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) beverage
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL) beverage
Number of subjects: 8
Study: 1297516

Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy examination of optic nerve head and disc pallor measurement from disc photographs
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comparison of two methods for detecting early glaucomatous damage
Number of subjects: 120
Study: 6835771

Group type: EXPERIMENTAL
Intervention: Sibling visiting
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonvisiting group
Number of subjects: 16
Study: 30415255

Group type: EXPERIMENTAL
Intervention: mPCNL with ureter catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: partial tubeless mPCNL
Number of subjects: 60

Group type: COMPARATOR
Intervention: mPCNL
Number of subjects: 60
Study: 29927289

Group type: EXPERIMENTAL
Intervention: Positive marital discussion
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conflict marital discussion
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Secure base script knowledge
Number of subjects: 115
Study: 27528522

Group type: EXPERIMENTAL
Intervention: Multistep adaptive framework intervention in intervention ASPs
Number of subjects: 1700
Study: 24643810

Group type: EXPERIMENTAL
Intervention: Pressure-monitored group (maintaining intra-cuff pressure below 60 cm H2O)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care group (control group, no further action taken)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 22169620

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (vitamin K(2)) treatment at 45, 135, or 360 μg/d for 6 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy age-matched individuals)
Number of subjects: 53
Study: 19154562

Group type: EXPERIMENTAL
Intervention: Partial intervention
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 1575

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1575
Study: 18236186

Group type: EXPERIMENTAL
Intervention: 1 mg ibandronate (1 mL) applied to the tibial bone surface 1 min before cementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 mL saline applied to the tibial bone surface 1 min before cementation
Number of subjects: 50
Study: 15785256

Group type: EXPERIMENTAL
Intervention: Exercise group (supervised stretching, balance, endurance, coordination, and strengthening exercises for 6 weeks)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (attended seminars)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 12572648

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spectrum‐TPH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dyract/TPH (sandwich)
Number of subjects: 23
Study: 9448204

Group type: EXPERIMENTAL
Intervention: 2 gm of ascorbic acid (vitamin C) combined with 1000 IU of d-alpha-tocopherol (vitamin E)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8586527

Group type: EXPERIMENTAL
Intervention: i.v. essential amino acids (EAA) solution 13.4 g daily + dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Number of subjects: 50
Study: 2527048

Group type: EXPERIMENTAL
Intervention: glutamyl-L-dopa (gludopa)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 782685

Group type: EXPERIMENTAL
Intervention: COP (cyclophosphamide, vincristine, prednisone)
Number of subjects: 113

Group type: COMPARATOR
Intervention: CO (cyclophosphamide, vincristine)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: COP
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Extended maintenance CO treatment
Number of subjects: 113
Study: 31104005

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM), exercise, and cold therapy
Number of subjects: 40
Study: 31465157

Group type: EXPERIMENTAL
Intervention: Ruptured cAVMs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Unruptured cAVMs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-grade (SM grade) ruptured cAVMs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low-grade (SM grade) ruptured cAVMs
Number of subjects: 70
Study: 29154072

Group type: EXPERIMENTAL
Intervention: Viewing fresh roses for 3 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: No experimental stimulus (control)
Number of subjects: 15
Study: 24692302

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg BW)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 363
Study: 23718959

Group type: EXPERIMENTAL
Intervention: 15-month intervention
Number of subjects: 0
Study: 21665501

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine preparation with no regard to eyebrows (Group A)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine preparation with eyebrows excluded (Group B)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine preparation with bladed lid speculum (Group C)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard preparation)
Number of subjects: 77
Study: 18671796

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (INT)
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Improved standard glycaemic control (STD)
Number of subjects: 1791
Study: 16935870

Group type: EXPERIMENTAL
Intervention: Azimilide (125 mg o.d.)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Sotalol (160 mg b.i.d.)
Number of subjects: 658
Study: 15342288

Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (3,000 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1,500 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 10899248

Group type: EXPERIMENTAL
Intervention: 5 TU tuberculin skin test
Number of subjects: 128

Group type: COMPARATOR
Intervention: 10 TU tuberculin skin test
Number of subjects: 128
Study: 9036320

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm)
Number of subjects: 235

Group type: COMPARATOR
Intervention: 100% oxygen (control)
Number of subjects: 235
Study: 8395712

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH) administered subcutaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient LMWH therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-hospital care
Number of subjects: 0
Study: 2868659

Group type: EXPERIMENTAL
Intervention: Alpha blocker (prazosin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 29363103

Group type: EXPERIMENTAL
Intervention: Combined epidural-general anaesthesia (Epi-GA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 128
Study: 27140926

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study: 24571163

Group type: EXPERIMENTAL
Intervention: Self-care in Chronic Conditions Partners in Health Scale instrument
Number of subjects: 552
Study: 23766350

Group type: EXPERIMENTAL
Intervention: Complete revascularization (CR) with a residual SYNTAX Score of 0 (n=386, 42.7%)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX Score >0 to 4 (ICR) (n=184, 20.4%)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX Score >4 to 8 (ICR) (n=167, 18.5%)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX Score >8 (ICR) (n=153, 16.9%)
Number of subjects: 903
Study: 20925605

Group type: EXPERIMENTAL
Intervention: Saline wound irrigation before wound closure
Number of subjects: 520

Group type: COMPARATOR
Intervention: No saline wound irrigation (Control)
Number of subjects: 520
Study: 18979587

Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (FG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 16521637

Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12698315

Group type: EXPERIMENTAL
Intervention: Water (750 ml)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline solution (750 ml)
Number of subjects: 19
Study: 10491472

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4